Can a Two-Pronged radiation strategy boost immunotherapy against advanced nasopharyngeal cancer?

This trial is testing whether a special type of radiation called radscopal radiotherapy—which combines low-dose radiation to the main tumor and precise high-dose radiation to distant metastases—can enhance the effects of two immunotherapy drugs (sintilimab and ipilimumab) in people with metastatic nasopharyngeal carcinoma who cannot receive chemotherapy. The study aims to see if this combination can shrink tumors, control the disease throughout the body, and improve survival, while also being safe and tolerable. Participants will receive the treatment for up to six months, and researchers will monitor their response and any side effects.